- Home
- EBMT vs BDTX Comparison
EBMT vs BDTX Comparison
Compare EBMT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBMT | BDTX |
|---|---|---|
| Founded | 1922 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 171.9M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EBMT | BDTX |
|---|---|---|
| Price | $22.23 | $2.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $24.00 | $9.67 |
| AVG Volume (30 Days) | 33.8K | ★ 506.7K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | 53.23 | ★ 130.71 |
| EPS | ★ 0.98 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $22.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.80 | $1.60 |
| 52 Week High | $24.66 | $4.94 |
Technical Indicators
Market Signals| Indicator | EBMT | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.53 | 50.72 |
| Support Level | $21.66 | $1.98 |
| Resistance Level | $22.87 | $2.28 |
| Average True Range (ATR) | 0.65 | 0.10 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 27.04 | 20.00 |
Price Performance
Historical ComparisonAbout EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.